Company Overview
Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for virology and immunology indications. The company's product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; zelicapavir and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; EDP-978 for chronic spontaneous urticaria (CSU); Glecaprevir, antiviral protease inhibitors for the treatment of chronic infection with hepatitis C virus or HCV; and EPS-3903 for the treatment of atopic dermatitis. It has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. The company was incorporated in 1995 and is headquartered in Watertown, Massachusetts.
Why Investors Should Care
Generates positive free cash flow, funding growth and shareholder returns internally.
Recent Developments
- Sep 2025 Revenue of $65.32M (-3.4% YoY); net profit $-81.89M.
- Trailing 12 Months Year-on-year growth — revenue +15.0%.
- 5-Year Trend Long-term compounding — revenue CAGR 3.2%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 3.23% |
| 1 Year: | 15.00% |
Stock Price Performance
| 1 Year: | +88.36% |
| 6 Months: | +0.00% |
| 3 Months: | -8.13% |
| 1 Month: | +13.90% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)44.68 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Generates positive free cash flow.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
No notable concerns flagged.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | ENTA Enanta Pharmaceuticals, Inc. R2K | 13.11 | -5.04 | $381.22M | 0.00% | -36.76% | -59.00% | 3.23% | - |
| 2 | LLY Eli Lilly and Company SPX | 1,152.54 | 41.02 | $1.03T | 0.61% | - | 107.46% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPX | 253.85 | 29.45 | $611.07B | 2.23% | 14.88% | 26.42% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPX | 244.78 | 119.40 | $432.48B | 3.04% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | UNH UnitedHealth Group Incorporated SPX | 425.19 | 32.02 | $386.13B | 2.27% | 9.74% | 12.18% | 10.40% | 5.43% |
| 6 | MRK Merck & Co., Inc. SPX | 120.78 | 34.02 | $298.31B | 2.86% | - | 18.94% | 5.64% | 10.01% |
| 7 | AZN AstraZeneca PLC NDX | 164.50 | 24.81 | $255.12B | 1.77% | 15.97% | 23.48% | 9.82% | 45.96% |
| 8 | TMO Thermo Fisher Scientific Inc. SPX | 534.07 | 29.33 | $198.47B | 0.40% | 8.14% | 13.52% | 8.81% | 12.95% |
| 9 | AMGN Amgen Inc. NDXSPX | 355.25 | 24.69 | $191.73B | 2.84% | 18.02% | 101.32% | 11.77% | 5.58% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2015 | Jun 2015 | Sep 2015 | Dec 2015 | Mar 2016 | Jun 2016 | Sep 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | 10.42M | 8.96M | 7.51M | 75.93M | 38.11M | 44.05M | 57.26M | 67.20M | 69.89M | 39.63M | 44.37M | 51.31M | 52.57M | 27.62M | 18.65M | 23.63M | 31.74M | 20.13M | 21.62M | 27.65M | 18.72M | 19.48M | 23.59M | 17.80M | 18.89M | 18.00M | 17.05M | 17.97M | 16.96M | 14.93M | 18.31M | 18.61M | 17.16M |
| Operating Income | 48.56M | 1.70M | - | 35.59M | -565.00K | -1.09M | - | -7.05M | -9.51M | -13.13M | - | 14.38M | 16.86M | 22.64M | - | 27.86M | -1.30M | 3.75M | - | 12.87M | -11.88M | -22.85M | - | -12.30M | -29.70M | -33.85M | -30.41M | -33.85M | -32.54M | -30.01M | -39.45M | -36.71M | -34.89M | -32.77M | -24.18M | -23.54M | -24.53M | -18.89M | -11.25M | -11.85M |
| Net Income | 28.75M | 2.42M | 5.81M | 26.19M | -1.65M | -1.08M | -1.80M | -4.98M | -5.39M | -8.43M | 36.51M | 11.69M | 12.55M | 20.29M | 27.42M | 26.01M | 4.14M | 7.04M | 9.19M | 13.44M | -6.00M | -14.27M | -29.34M | -8.33M | -22.05M | -24.02M | -30.11M | -33.59M | -31.70M | -28.99M | -37.66M | -39.06M | -33.41M | -31.16M | -22.66M | -22.29M | -22.64M | -18.25M | -11.94M | -13.09M |
| Diluted EPS | 1.49 | 0.13 | 0.29 | 1.37 | -0.09 | -0.06 | -0.09 | -0.26 | -0.28 | -0.44 | 1.86 | 0.59 | 0.61 | 0.97 | 1.30 | 1.25 | 0.20 | 0.33 | 0.44 | 0.65 | -0.30 | -0.71 | -1.46 | -0.41 | -1.09 | -1.19 | -1.48 | -1.63 | -1.53 | -1.39 | -1.79 | -1.86 | -1.58 | -1.47 | -1.07 | -1.05 | -1.06 | -0.85 | -0.42 | -0.45 |
| R&D Expense | 5.37M | 6.25M | - | 9.03M | 9.14M | 10.79M | - | 12.53M | 13.00M | 15.41M | - | 17.96M | 21.48M | 28.49M | - | 34.88M | 34.16M | 34.46M | - | 32.78M | 32.61M | 34.68M | - | 36.66M | 41.51M | 46.99M | 48.55M | 42.09M | 39.09M | 40.90M | 43.47M | 42.99M | 36.37M | 35.59M | 28.74M | 27.66M | 28.07M | 27.21M | 20.86M | 19.44M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Sep 2011 | Sep 2012 | Sep 2013 | Sep 2014 | Sep 2015 | Sep 2016 | Sep 2017 | Sep 2018 | Sep 2019 | Sep 2020 | Sep 2021 | Sep 2022 | Sep 2023 | Sep 2024 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 41.88M | 41.71M | 32.05M | 47.74M | 160.88M | 88.27M | 102.81M | 206.62M | 205.20M | 122.47M | 97.07M | 86.16M | 79.20M | 67.64M | 65.32M |
| Operating Income | 25.30M | 21.29M | 9.03M | 18.98M | 124.15M | 30.84M | 24.61M | 88.33M | 36.74M | -41.64M | -109.57M | -123.84M | -137.21M | -121.69M | -85.35M |
| Net Income | 23.31M | 21.40M | 9.63M | 34.44M | 78.99M | 21.67M | 17.71M | 71.96M | 46.38M | -36.17M | -79.00M | -121.75M | -133.82M | -116.05M | -81.89M |
| Diluted EPS | 1.32 | 1.13 | -0.67 | 1.80 | 4.09 | 1.13 | 0.91 | 3.48 | 2.21 | -1.81 | -3.92 | -5.91 | -6.38 | -5.48 | -3.84 |
| R&D Expense | 11.55M | 15.12M | 16.84M | 18.74M | 23.19M | 40.46M | 57.45M | 94.86M | 142.21M | 136.76M | 174.11M | 164.52M | 163.52M | 131.48M | 106.74M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Sep 2010 | Sep 2011 | Sep 2012 | Sep 2013 | Sep 2014 | Sep 2015 | Sep 2016 | Sep 2017 | Sep 2018 | Sep 2019 | Sep 2020 | Sep 2021 | Sep 2022 | Sep 2023 | Sep 2024 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 52.16M | 116.97M | 155.41M | 246.01M | 281.28M | 326.64M | 414.23M | 489.83M | 486.13M | 438.79M | 375.41M | 462.27M | 376.65M | 280.73M |
| Total Equity | -150.07M | -131.96M | -115.35M | 110.47M | 148.65M | 236.16M | 269.94M | 301.68M | 393.68M | 462.49M | 455.58M | 399.43M | 321.33M | 216.74M | 128.81M | 64.72M |
| Cash & Equivalents | 466.00K | 6.84M | 10.51M | 8.86M | 30.70M | 21.73M | 16.58M | 65.67M | 63.90M | 51.23M | 87.13M | 57.21M | 43.99M | 85.39M | 37.23M | 32.30M |
| Total Liabilities | - | - | 8.23M | 6.50M | 6.76M | 9.86M | 11.34M | 24.96M | 20.55M | 27.34M | 30.55M | 39.36M | 54.08M | 245.54M | 247.84M | 216.01M |
| Current Liabilities | - | - | 5.73M | 4.53M | 4.75M | 6.70M | 7.89M | 20.98M | 16.02M | 22.61M | 24.16M | 36.17M | 29.83M | 62.79M | 57.53M | 48.55M |
Cash Flows (Annual)
Figures in USD.
| Metric | Sep 2011 | Sep 2012 | Sep 2013 | Sep 2014 | Sep 2015 | Sep 2016 | Sep 2017 | Sep 2018 | Sep 2019 | Sep 2020 | Sep 2021 | Sep 2022 | Sep 2023 | Sep 2024 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | 24.02M | 22.62M | 10.65M | - | - | 35.81M | 52.65M | 29.22M | 71.42M | 7.09M | -70.00M | -84.78M | -103.15M | -78.76M | -19.27M |
| Investing Cash Flow | -17.68M | -18.04M | -69.22M | - | - | -43.66M | -4.57M | -35.40M | -86.66M | 19.83M | 36.99M | 54.90M | -53.58M | 58.23M | 40.35M |
| Financing Cash Flow | 34.00K | -909.00K | 56.91M | - | - | 2.71M | 1.02M | 4.41M | 2.57M | 8.98M | 3.08M | 20.03M | 198.13M | -27.63M | -26.62M |
| Capital Expenditure | -445.00K | -252.00K | -606.00K | -1.03M | -2.34M | -4.74M | -2.51M | -2.98M | -5.42M | -1.45M | -750.00K | -2.12M | -9.06M | -17.95M | -12.90M |
| Free Cash Flow | 23.57M | 22.37M | 10.05M | - | - | 31.07M | 50.15M | 26.24M | 66.00M | 5.64M | -70.75M | -86.91M | -112.21M | -96.71M | -32.17M |
Ratios (Annual)
Figures in %.
| Metric | Sep 2011 | Sep 2012 | Sep 2013 | Sep 2014 | Sep 2015 | Sep 2016 | Sep 2017 | Sep 2018 | Sep 2019 | Sep 2020 | Sep 2021 | Sep 2022 | Sep 2023 | Sep 2024 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Margin % | 60.4% | 51.0% | 28.2% | 39.8% | 77.2% | 34.9% | 23.9% | 42.7% | 17.9% | -34.0% | -112.9% | -143.7% | -173.2% | -179.9% | -130.7% |
| Net Margin % | 55.7% | 51.3% | 30.0% | 72.1% | 49.1% | 24.5% | 17.2% | 34.8% | 22.6% | -29.5% | -81.4% | -141.3% | -169.0% | -171.6% | -125.4% |
| ROE % | -17.7% | -18.6% | 8.7% | 23.2% | 33.4% | 8.0% | 5.9% | 18.3% | 10.0% | -7.9% | -19.8% | -37.9% | -61.7% | -90.1% | -126.5% |
| ROCE % | - | 45.9% | 8.0% | 12.6% | 51.9% | 11.3% | 8.1% | 22.2% | 7.9% | -9.0% | -27.2% | -35.8% | -34.3% | -38.1% | -36.8% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Janus Henderson Group PLC | 13.01% | 3.78M | $55.47M |
| 2 | Blackrock Inc. | 10.67% | 3.10M | $45.50M |
| 3 | Farallon Capital Management LLC | 9.88% | 2.87M | $42.10M |
| 4 | Krensavage Asset Management, LLC | 9.86% | 2.87M | $42.02M |
| 5 | Deep Track Capital, Lp | 6.73% | 1.96M | $28.69M |
| 6 | Vanguard Capital Management LLC | 4.05% | 1.18M | $17.27M |
| 7 | Vanguard Portfolio Management LLC | 3.26% | 948.90K | $13.91M |
| 8 | Spruce Street Capital LP | 3.21% | 932.60K | $13.67M |
| 9 | Acadian Asset Management. LLC | 3.03% | 880.02K | $12.90M |
| 10 | Millennium Management Llc | 3.03% | 882.10K | $12.93M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for ENTA
(ENTA) Movement as an Input in Quant Signal Sets - Stock Traders Daily
<a href="https://news.google.com/rss/articles/CBMixAFBVV95cUxOYWtfOVF2bVM1bS12YnRfZHgwOXlrV3RSU0pNQUVZSHdkVVNFSjB5Mk1ZcjJZM2ZPQjZQYzhKVXBhNXBHNjRIOGEwMTQ1YU1KWXd1OFdmYUYzMWpuMUhPT1Jsbk9nZjNGNkQ1dFdDLXJWbHFjTWx6VHJfT1hSdGFGbklhcVNiUktsRHdfYX…
Enanta Pharmaceuticals (ENTA) Moves 5.2% Higher: Will This Strength Last? - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMiogFBVV95cUxPOVV5cjlXMFpBM0J1TFR6NUN5QXRTMUdNSVBFVnk2czNweERhc0NTT3hqX3FmSnJWdTQwUk4tMWREa3QxTmxNQWlKV0ZRZGo2cmM3RXdtemlyczZaN0l3dF9pS3JXdFJzcEhYQVpiOVJhUW1MWmdiOE5IU25QU1NqanNCTTgwOHlqQUVOS3…
ENTA Forecast — Price Target — Prediction for 2027 - TradingView
<a href="https://news.google.com/rss/articles/CBMiekFVX3lxTFBzR3ZHUkRLOXJmSW4zSHFzNklKQ0ZZM1FMeDZaUUdCU01DQndKeGd5dThmRy1xVERBd3dZREQ3MFp2cmpERHBhWGtseV91Vk1OUEZieG5oNjBEWExyQ3QxcW1JTzlWNk80M1hrQnA4T0xEYzY2NEtONFF3?oc=5" target="_blank">ENT…
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Stock Catapults 27% Though Its Price And Business Still Lag The Industry - simplywall.st
<a href="https://news.google.com/rss/articles/CBMi7AFBVV95cUxPODRPaXJrRU9WMlVoSXZjTWV6Mm81cV9tbkJwUzkxQmJsLUhLa0tfYlMzbWJCYVVERFl4d2FGSWdOZExlZjYtUWNrYTR0S05ranQ3cFpLbmNhc05DcHpHYTJCeXpzVzNIeEZrd3VCY2ZqY0E5U2VscHdhTlhqZXpLVU4xOTFxMU42NVZ2Rm…
Enanta Pharmaceuticals Reports Financial Results for its Fiscal Second Quarter Ended March 31, 2026 - Business Wire
<a href="https://news.google.com/rss/articles/CBMi6wFBVV95cUxNLUJXRkxoZDY2b0dEN1ZBSmtieHZ3YzNHZVA4SHgwR3ZoQUlmU25EZnFpNGg3Y2ljc0pCTmFldElvRHE5TWRRZzlBSHdwQmRwbEpUMUxTUk1lOXVlSGlmYm80bkV3RmRGaTJhRnlPb2JSR2pRYXhnNzBjUnVrZEplSTRqaWJwdV9UdTJFcE…
Enanta Enters $75 Million At-the-Market Stock Offering Agreement - Moomoo
<a href="https://news.google.com/rss/articles/CBMiqAFBVV95cUxPMHBSNkZjaFl0UHJ5c3hnUlM2NkZESHZOTFYydDlJS0lEU1FsRXI1VVBHVlpWOUpMem5VQjFjZlZmZW1adG9QVTZIN1RKS1h5eEJmV2ZXS2hybXRZdFJtbUhiVUlZWU9RaFVnU3JBQVV2T1QwdDJBYnkycktPaEhhUm5PaVZQLXJuRlZsRl…
ENTA — Frequently Asked Questions
What is the current share price of Enanta Pharmaceuticals, Inc. (ENTA)?
As of 2026-07-14 21:23 PDT, Enanta Pharmaceuticals, Inc. (ENTA) trades at $13.11 on NasdaqGS. Its 52-week range is $6.49 to $16.85.
What is the market capitalisation of ENTA?
Enanta Pharmaceuticals, Inc. (ENTA) has a market capitalisation of $381.22M on NasdaqGS.
What is the P/E ratio of ENTA?
ENTA trades at a trailing price-to-earnings (P/E) ratio of -5.04. The industry average P/E is 25.41. Its price-to-book (P/B) ratio is 2.97.
What is the return on equity (ROE) of ENTA?
ENTA has a return on equity (ROE) of -59.00%. Its return on capital employed (ROCE) is -36.76%.
Is ENTA a good stock to buy?
This page provides a data-driven analysis of Enanta Pharmaceuticals, Inc. (ENTA), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.